

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sino Harbour Holdings Group Limited

漢港控股集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 1663)

VOLUNTARY ANNOUNCEMENT

ZHEJIANG IPS, A SUBSIDIARY OF THE COMPANY, HAS BEEN CERTIFIED AS A ZHEJIANG PROVINCIAL HIGH AND NEW TECHNOLOGY ENTERPRISE R&D CENTRE

This announcement is made by Sino Harbour Holdings Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development of the Company.

The board of directors of the Company (the “**Directors**” and the “**Board**”, respectively) is pleased to announce that Zhejiang IPS Pharmaceutical Technology Company Limited (浙江美測醫藥科技有限公司) (“**Zhejiang IPS**”, a subsidiary of the Company) has been certified as a Zhejiang Provincial High and New Technology Enterprise R&D Centre by the Zhejiang Provincial Department of Science and Technology. Forming an important part of the technological innovation system of Zhejiang Province, the Zhejiang Provincial High and New Technology Enterprise R&D Centres are in line with the vision of the Zhejiang Provincial Department of Science and Technology of thoroughly implementing the overall planning of the provincial party committee and the provincial government to comprehensively accelerate technological innovation and promote high-quality development. Based on the inspection, evaluation and recommendation by the science and technology bureaus of different districts and cities as well as expert reviews, the Zhejiang Provincial High and New Technology Enterprise R&D Centres are enterprises that meet the conditions for the establishment of provincial-level high and new technology enterprise research and development centres.

Being certified as a provincial high and new technology enterprise R&D centre is a significant recognition of the growth as well as the research and development capabilities of Zhejiang IPS. This certification also marks another milestone for Zhejiang IPS in a short period of time after being certified as a Hangzhou Municipal Enterprise High and New Technology R&D Centre in August 2022. Besides being a significant recognition of the research and development strength of Zhejiang IPS, the certification also highlights the fact that the Company's investments over the years have begun to pay off.

The Company is of the view that Zhejiang IPS has been committed to providing customers with efficient, high-tech, and high-standard professional research and development services, as well as creating a one-stop service platform for the research and development of innovative drugs and generic drugs. As the Group continues to increase its investments in hardware, software and talent, and accelerate the implementation of scientific and technological achievements to establish an enterprise-based regional innovation system, Zhejiang IPS will become one of the leading comprehensive pharmaceutical technology companies in China in the future.

Shareholders and/or potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

For and on behalf of
Sino Harbour Holdings Group Limited
WONG Lam Ping
*Chairman, Chief Executive Officer,
Executive Director and General Manager*

Hong Kong, 11 January 2023

As at the date of this announcement, the executive Directors are Mr. WONG Lam Ping (Chairman, Chief Executive Officer and General Manager), Mr. SHI Feng (Deputy Chairman), Mr. WONG Lui and Ms. GAO Lan; the non-executive Director is Mr. CHAN Kin Sang; and the independent non-executive Directors are Mr. XIE Gang, Mr. HE Dingding and Mr. WONG Ping Kuen.